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Introduction
Th e systemic vasculitides include a diverse range of 
conditions characterised by leucocyte infi ltration of 
blood vessel walls, fi brinoid necrosis and vascular 
damage with occlusion or aneurysm formation. Th ese 
conditions may be primary in origin, when they are 
classifi ed according to the predominant size of vessel 
aff ected [1] (Table  1), or secondary to infection, malig-
nancy, drugs or another autoimmune process, such as 
rheumatoid arthritis or systemic lupus erythematosus 
(SLE). Of the primary systemic vasculitides, the most 
prevalent syn drome is autoantibodies to neutrophil 
cytoplasmic antigens (ANCA)-associated vasculitis 
(AAV), which has attracted the most attention in the 
optimisation of existing therapies and the introduction of 
newer agents. AAV will be the focus of this review.
ANCA-associated vasculitis
AAV includes (Wegener’s) granulomatosis with poly angi-
itis (GPA), microscopic polyangiitis (MPA) and Churg-
Strauss syndrome (CSS). Th ese conditions are usually 
associated with the presence of circulating ANCA [2]. Th e 
pathogenicity of ANCA has been confi rmed in experi-
mental models [3]. AAV predominantly involves 
microscopic blood vessels, with the respiratory tract and 
kidneys being the most common organs aff ected, although 
immune deposits are scanty [1,4]. AAV has an annual 
incidence of 20 per million and a prevalence over 200 per 
million [5]. Across the spectrum of AAV, disease is sub-
classifi ed according to the severity and extent of organ 
involvement, ranging from localised to severe organ-
threatening or life-threatening disease [6] (Table  2). Th is 
subclassifi cation underlies current treatment guidelines, 
and has contributed to the design of clinical trials to ensure 
comparable patients are enrolled across multiple centres.
Current treatment outcomes
Prior to eff ective treatment, AAV had a mortality of 93% 
within 2  years, primarily due to renal and respiratory 
failure [7]. Th e introduction of glucocorticoids in 1948 
and cyclophosphamide in the 1960s, together with ad-
junc tive therapies such as antihypertensive drugs and 
renal replacement therapy, has transformed survival – 
with 5-year survival rates now approaching 80% [6]. Th is 
therapeutic revolution has converted vasculitis into a 
chronic relapsing disorder with progressive organ 
damage and disability, eventually aff ecting over 95% of 
patients. Th e cumulative exposure to glucocorticoids and 
immunosuppressive drugs contributes to organ damage, 
and there has been particular concern caused by cyclo-
phosphamide-related toxicities of myelosuppres sion, 
infections, urothelial malignancy and infertility [8,9]. 
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Rates of cardiovascular disease and malignancy are 
increased and it is unclear to what extent these refl ect the 
underlying disease process or its treatment [10]. Early 
treatment-related leucopaenia and infection, and later 
cardiovascular disease, are now the predominant causes 
of death, rather than uncontrolled vasculitis [11].
Treatment-related toxicity, together with the 10 to 30% 
of patients who do not respond to traditional immuno-
suppressive agents and pursue a refractory course and 
the 50% of patients who relapse within 5  years despite 
continued immunosuppression, has shifted the focus of 
treatment for AAV [12]. From learning how to best use 
traditional agents to minimise toxicity without losing 
effi  cacy, to the advent of new targeted biological agents, a 
second revolution in the treatment of AAV is on the 
horizon.
Pathogenesis of AAV
Both genetic susceptibility and environmental exposures 
contribute to the aetiology of AAV. ANCA have been 
demonstrated pathogenic in animal models but their 
contribution to human disease remains unclear. Transfer 
of murine myeloperoxidase-ANCA IgG to mice without 
functioning B cells or T cells results in a pauci immune, 
necrotising crescentic glomerulonephritis, similar to that 
seen in AAV in humans [3]. Human anti-PR3 antibodies 
from individuals with AAV were recently demonstrated 
to cause comparable renal and pulmonary lesions in mice 
with a humanised immune system [13]. Two lines of 
investigation have linked infections to ANCA formation 
through molecular mimicry [14,15]. Fimbriated bacteria 
can induce novel ANCA, antibodies to human lysosome 
membrane protein-2, which can induce a crescentic 
glomerulo nephritis in animal models [15]. Microbial 
superantigens are responsible for T-cell dysregulation in 
Kawasaki disease [16], and infection with Staphylococcus 
aureus is associated with relapse of GPA [17,18]. In 
sensitive assays, the PR3–ANCA binding level is 
predictive of outcome and rises in ANCA precede 
relapse. Th e clinical correlation with ANCA is closest for 
alveolar and glomerular capillaritis, both lesions capable 
of being induced by ANCA in experimental models. 
Patients who are consistently ANCA-negative, however, 
may fi t the clinical phenotype of AAV, and the effi  cacy of 
B-cell depletion with rituximab is not associated with 
ANCA status. Despite the pauci immune nature of the 
histology in ANCA vasculitis, there is evidence of a role 
for immune complexes and complement activation in 
renal vasculitis.
Th ere is activation of circulating T lymphocytes and B 
lymphocytes and infi ltration of plasmoblasts into aff ected 
tissues [19]. Autoreactive B cells are necessary for the 
development of autoantibody-producing cells, but may 
play a more important role in supporting autoreactive T-
cell activity through antigen presentation, co-stimulation 
and the direct production of proinfl ammatory cytokines, 
such as IL-6 and TNFα. In view of their role as precursors 
of ANCA-secreting plasma cells, B cells are a therapeutic 
target in AAV. T cells also play an important role in the 
pathogenesis of AAV [20]. Th e autoantibodies are class 
switched (that is, mainly IgG), which means the 
autoreactive B cell has received cognate T-cell help. Also, 
in biopsy specimens T cells are seen to infi ltrate tissues, 
causing damage via direct cytotoxicity and by the 
recruitment and activation of macrophages [21]. A CD8 
T-cell gene expression signature has been associated with 
relapse frequency in AAV [22], and T-cell targeted 
therapies including cyclosporin [23] and alemtuzumab 
have been eff ective [24].
Treatment
After making a diagnosis of systemic vasculitis, treatment 
is divided into remission induction, then 3 to 6 months of 
intensive therapy, followed by a longer period of remission 
maintenance therapy. Disease state defi nitions have been 
agreed for active disease, remission, low disease activity 
state and refractory disease [25]. Further key manage-
ment concepts are the subgrouping of patients by 
severity, the minimisation of adverse event risk and 
proactive management of increased cardiovascular and 
malignancy risks.
GPA has been subdivided into limited or nonsevere 
versus generalised or severe – the most important deter-
mi nant being the presence or absence of nephritis. An 
analogous system was developed by the European 
Vasculitis Study Group to include both GPA and MPA 
(Table 2) [25] in order to defi ne eligibility for a sequence 
of randomised controlled trials aimed at defi ning the 
optimal standard of care.
Standard induction remission therapy
Glucocorticoids
Despite the introduction of glucocorticoids into treat-
ment strategies for vasculitis over 50 years ago, there are 
Table 1. Classifi cation of systemic vasculitis
Small vessel Granulomatosis with polyangiitis
 Microscopic polyangiitis
 Churg-Strauss syndrome
 Henoch Schönlein purpura
 Cryoglobulinaemic angiitis
 Cutaneous leucocytoclastic vasculitis
Medium vessel Polyarteritis nodosa
 Kawasaki disease
Large vessel Giant cell arteritis
 Takayasu arteritis
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no randomised controlled trials to support their use. 
Evidence is also lacking to guide dosage. Current 
regimens start oral prednisone/prednisolone at 1 mg/kg/
day, reducing to 10 to 20 mg daily by 12 weeks, with up to 
3 g intravenous (i.v.) methylprednisolone for generalised 
or severe presentations. Although they contribute to 
disease control, there is increasing evidence that high-
dose steroids contribute to morbidity [26]. Th e PEXIVAS 
trial aims to address the effi  cacy of a rapidly reducing 
glucocorticoid regimen, as well as the place of plasma 
exchange in severe AAV (ClinicalTrials.gov: NCT00987389).
Cyclophosphamide
Cyclophosphamide, together with high-dose gluco corti-
coids, was introduced empirically for induction treatment 
of AAV over 40  years ago, as a lymphocyte-depleting 
therapy following its use in lymphoproliferative diseases. 
Together with glucocorticoids, cyclophosphamide remains 
the standard of care in consensus guidelines for the 
treatment of generalised disease [27]. Th e use of cyclo-
phosphamide has been refi ned, however, employing 
strategies to reduce exposure and cumulative toxicity.
Th e effi  cacy of a sequential design whereby cyclophos-
phamide was replaced by an alternative at the time of 
remission was explored in the CYCAZAREM trial [28]. 
In this study, 155 patients were randomised to receive 
either 1  year of oral cyclophosphamide or 3  months 
(maximum 6 months) of oral cyclophosphamide followed 
by azathioprine. Both groups followed a similar steroid 
taper. Th ere was no diff erence in relapse rates between 
the two groups at 18  months, demonstrating that the 
duration of exposure to cyclophosphamide may be safely 
reduced.
An i.v. pulsed administration has potential advantages 
over daily oral cyclophosphamide of reduced exposure, 
bladder protection and improved compliance. A meta-
analysis of three studies of i.v. cyclophosphamide, includ-
ing 143 patients, demonstrated that pulsed regimens 
reduced cumulative cyclophosphamide exposure by 50%, 
and were at least as eff ective at inducing remission, with 
fewer infective and myelosuppressive side eff ects but 
possibly with an increased risk of relapse [29].
Th e CYCLOPS study randomised 149 patients with 
generalised AAV to receive either i.v. cyclophosphamide, 
15 mg/kg at 2-week intervals for the fi rst three doses and 
every 3 weeks thereafter, or daily oral cyclophosphamide 
2  mg/kg/day [30]. Induction therapy was continued for 
3  months after remission was achieved in both groups 
prior to a switch to azathioprine for maintenance therapy 
until the end of the 18-month trial. Th ere was no 
diff erence in time to achieve remission or the proportion 
of patients in remission at 9 months between the groups, 
despite the i.v. cyclophosphamide group receiving 8.2  g 
as compared with 15.9 g cyclophosphamide for the daily 
oral route. Th e reduced dose resulted in fewer leuco-
paenic episodes, but this did not translate to fewer infec-
tions. Long-term follow-up (median 4.3 years), however, 
has shown that pulsed i.v. cyclophosphamide is 
Table 2. EUVAS disease categorisation of and randomised controlled trials in AAV according to disease severity
Category Defi nition Induction Trial Maintenance Trial
Localised One site aff ected, often upper 
respiratory tract
(Co-trimoxazolea) Co-trimoxazole Stegeman and 
colleagues [57]
Early systemic Any disease, without imminent 
vital organ failure
MTX or CYC + GC NORAM [32] Co-trimoxazole Stegeman and 
colleagues [57]
Generalised Renal or other organ threatening 
disease, creatinine <500 μmol/l
CYC+ GC CYCLOPS [30] AZA + GC CYCAZAREM [28]
RTX + GC RAVE [43] MTX + GC WEGENT [55]
MMF + GC Hu and colleagues [46] Lefl unomide Metzler and 
colleagues [56]
AZA or MMF + GC IMPROVE [59]
Severe Renal or other vital organ failure, 
creatinine >500 μmol/l
CYC or RTX + GC RITUXVAS [42] AZA or MMF + GC IMPROVE [59]
PEX MEPEX [34]
Refractory Progressive disease 
unresponsive to steroids and 
cyclophosphamide
IVIg nonrandomised – 
RTX, DSG, MMF, ATG, IFX, 
HSCT, ALM
Jayne and colleagues 
[65]
No consensus
AAV, autoantibodies to neutrophil cytoplasmic antigen-associated vasculitis; ALM, alemtuzumab; ATG, anti-thymocyte globulin; AZA, azathioprine; CYC, 
cyclophosphamide; DSG, gusperimus; EUVAS, European Vasculitis Study Group; GC, glucocorticoids; HSCT, haemopoetic stem cell transplantation; IFX, infl iximab; IVIg, 
intravenous immunoglobulin; MMF, mycophenolate mofetil; MTX, methotrexate; PEX, plasma exchange; RTX, rituximab. aTrial proposed but not conducted.
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asso ciated with a higher relapse rate, but this does not 
seem to impact survival or long-term morbidity [31]. Th e 
CYCLOPS protocol also standardised cyclophosphamide 
dose reductions for age over 60  years and for renal 
impairment, which improved the safety of these regimens.
Methotrexate
Following nonrandomised studies of methotrexate in 
limited GPA, 100 patients with a new diagnosis of early 
systemic AAV, without critical organ manifestations and 
with creatinine <150 μmol/l were randomised to receive 
either methotrexate targeting 25  mg weekly or oral 
cyclophosphamide in the NORAM study [32]. Both 
groups followed the same glucocorticoid regimen, and 
treatment was withdrawn at 12 months. Methotrexate 
was not inferior at inducing remission, but remission was 
slower than with cyclophosphamide in those patients 
with more extensive disease or pulmonary involvement. 
Th ere was less leucopaenia with methotrexate, but more 
liver dysfunction and a higher relapse rate.
Adjunctive therapies for severe disease
For those presenting with severe vasculitis when vital 
organ function is already compromised, adjunctive 
therapies have been considered that include, plasma 
exchange, i.v. methylprednisolone, intravenous immuno-
globulin (IVIg) and TNFα blockade. Despite an absence 
of randomised evidence there is widespread use of i.v. 
methylprednisolone in doses between 1,000 and 3,000 mg 
for generalised and severe presentations.
Advanced renal failure at presentation correlates with 
an increased risk of end-stage renal failure and death, and 
the aims of therapy are both to control disease and 
recover organ function [6]. Several small trials have 
produced confl icting results regarding the merits of 
plasma exchange, although improvements in recovery 
rates for renal vasculitis presenting with advanced renal 
failure were found [33]. Th e MEPEX trial compared 
adjunctive therapy with plasma exchange or i.v. methyl-
prednisolone in 137 patients with AAV and serum 
creatinine >500  μmol/l (5.8  mg/dl) at presentation [34]. 
Both groups received oral cyclophosphamide and 
steroids. Plasma exchange decreased the risk of progres-
sion to end-stage renal failure by 24% at 12 months, but 
had no eff ect on longer-term renal function or survival 
[35].
Th e mode of action of plasma exchange is unclear, but 
removal of complement and coagulation factors, ANCA 
and other circulating factors is likely to be important. A 
smaller trial found benefi t in terms of renal outcome for 
patients presenting with less severe nephritis [36]. Th ere 
remains uncertainty regarding the long-term benefi ts of 
plasma exchange, and a recent meta-analysis failed to 
fi nd convincing evidence that there was an infl uence on 
the composite endpoint of death or end-stage renal 
disease after 1 year [37].
Severe alveolar haemorrhage is the most common 
vasculitic cause of early death, and, in view of similarities 
in pathogenesis with renal vasculitis, plasma exchange 
has been recommended. Single-centre reviews have 
suggested a role for plasma exchange, but one study of 
ventilator-dependent haemorrhage still found a 50% 
mortality despite this intervention [38,39].
Newer induction agents
B-cell depletion therapies (rituximab)
Following the successful use of rituximab in rheumatoid 
arthritis and increasing appreciation of a role for B cells 
in the pathogenesis of AAV, several studies have reported 
responses to ritxumab for patients with relapsing or 
refractory disease [40]. Th e largest multicentre series of 
65 patients with refractory disease reported complete 
remission in 75%, partial remission in 23%, and only one 
nonresponder. However, 57% of those who achieved 
remission relapsed after a median of 12 months [41].
Two randomised control studies – RITUXVAS [42], a 
randomised trial of a rituximab-based regimen versus 
cyclophosphamide in ANCA-associated renal vasculitis; 
and RAVE [43], rituximab for ANCA-associated 
vasculitis – have demonstrated that rituximab has similar 
effi  cacy to cyclophosphamide for the induction of 
remission in AAV. Table 3 summarises the key features of 
these studies.
Neither study reported a reduction in severe adverse 
events with rituximab, which suggested that high-dose 
glucocorticoids and the disease itself are the main 
contributors to these events, and that current cyclo-
phosphamide regimens are, in expert centres, reasonably 
safe. Although two doses of cyclophos phamide were 
administered in addition to rituximab in the RITUXVAS 
study, the RAVE study used no immunosuppressive in 
the rituximab group. Response rates were comparable, so 
it is now justifi ed to withdraw immunosuppression at the 
time of rituximab treatment. Th e response rates in both 
the rituximab and cyclophosphamide limbs of the RAVE 
study were lower in those patients who had 
glucocorticoids withdrawn by 6  months, highlighting 
their importance in remission induction strategies. 
However, this observation must be balanced against their 
longer-term toxicity, and the optimal time for withdrawal 
is yet to be established. For the subgroup presenting with 
relapsing disease as compared with new-onset disease, 
rituximab was more eff ective in obtaining remission than 
cyclophosphamide and can be recommended for this 
indication. Th e role of rituximab for new-onset disease is 
more controversial; both trials had a short duration of 12 
and 6  months, respectively, and longer-term results are 
awaited.
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Meanwhile rituximab can be recommended as an 
alternative to cyclophosphamide in generalised, severe or 
refractory AAV when the latter is contraindicated. 
However, controlled data for the use of rituximab in 
localised and early systemic disease are lacking at present.
Mycophenolate mofetil
Two observational studies reported remissions after myco-
phenolate mofetil (MMF) 2 g/day and gluco corti coids in 
25/32 (78%) patients with active, mostly relapsing, AAV 
and in 13/17 (76%) patients with MPA [44,45]. However, 
the former study found high rates of relapse [44].
Th irty-fi ve Chinese patients with MPA and serum 
creatinine <500  μmol/l (5.8  mg/dl) were randomised to 
either receive MMF 2 g/day or i.v. cyclophosphamide [46]. 
At 6 months, 14/18 (77.8%) of the MMF group compared 
with 8/17 (47.1%) in the cyclophosphamide group were in 
complete remission. In addition, 44.4% of patients in the 
MMF group recovered renal function compared with only 
16.7% in the cyclophosphamide group. Adverse events 
were comparable between the two groups. A larger 
induction trial to compare MMF and cyclophosphamide, 
involving 140 patients – the MYCYC trial – is being 
conducted by the European Vasculitis Study Group [47].
Remission maintenance therapy
AAV is a relapsing condition, with disease and treatment 
factors infl uencing relapse risk. In a retrospective cohort 
study of 246 patients with AAV and renal involvement, 
the relapse rate was 34% with a median time to relapse of 
13 months after induction of remission [12]. Aggregated 
data from four European Vasculitis Study Group trials, 
encompassing the spectrum of disease severity, reported 
a 50% relapse rate at 5  years (unpublished data), with a 
higher rate for GPA (70%) than for MPA (30%). Relapse 
risk is increased by upper respiratory tract involvement, 
nasal carriage of S. aureus infection and the absence of 
renal disease. Persistent ANCA positivity at the time of 
remission and a subsequent rise in ANCA level can be 
predictive of relapse [48-50]. Th e utility of ANCA 
monitor ing varies with disease type, however, and 
ongoing treatment dissociates changes in ANCA from 
changes in disease activity, which accounts for some 
negative reports [51].
Table 3. Comparison of trial design and preliminary data from the RITUXVAS and RAVE studies
 RITUXVAS trial [42] RAVE trial [43]
Patients (n) 44 – 33 RTX, 11 CYC 197 – 99 RTX, 98 CYC
New diagnosis (%) 100 49
Wegner’s granulomatosis:microscopic polyangiitis 1:1 3:1
PR3:myeloperoxidase (%) 58:42 67:33
Median age (years), RTX:CYC 68:67 54:51.5
Mean Birmingham Vasculitis Activity Score at entry, RTX:CYC 19:18 8.5:8.2
Renal function at entry, RTX:CYC 20:12 (GFR) 54:69 (creatinine clearance)
Rituximab dose 375 mg/m2×4 + two i.v. CYC pulses 375mg/m2×4
CYC dose 15 mg/kg i.v., six to 10 cycles 2 mg/kg/day per orally
Plasma exchange Yes No
Steroid dose 1 g i.v. methylprednisolone 1 to 3 g i.v. methylprednisolone
 1 mg/kg/day prednisolone per orally 1 mg/kg/day prednisolone per orally
 Decrease to 5 mg/day by 6/12 Decrease to 40 mg/day by 1/12
  Stop prednisolone by 6/12
Maintenance therapy CYC  AZA at 3 to 6 months CYC  AZA at 3 to 6 months
 RTX  none RTX  none
Primary endpoints 12 months 6 months
Remission (%), RTX:CYC 76:82 64:53 (no prednisolone)
  71:62 (<10 mg prednisolone)
Median time to remission (days), RTX:CYC 90:94 NR
Serious adverse events (%), RTX:CYC 42:36 22:33
Deaths, RTX:CYC 6:1 1:2
GFR at end of study, RTX:CYC 39:27 NR
CYC, cyclophosphamide; GFR, glomerular fi ltration rate; i.v., intravenous; NR, not recorded; RTX, rituximab.
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Withdrawal of immunosuppression or glucocorticoids 
is associated with a higher relapse rate [52]. Th e 
cyclophosphamide group had a relapse rate of 46.5% at 
18 months in the NORAM trial [32], when therapy was 
stopped at 12 months, compared with 13.7% at the same 
time point in the cyclophosphamide group in the 
CYCAZAREM trial [28], when azathioprine was sub sti-
tuted for cyclophosphamide at 12 months and continued 
until the end of the study. Consensus guidelines advocate 
continuation of maintenance immunosuppression for at 
least 18 to 24  months [27,53]. Th e REMAIN study is 
comparing the relapse rate between 2 years and 4 years of 
maintenance therapy [54].
Standard remission maintenance therapy
Azathioprine
Cyclophosphamide is eff ective at inducing remission in 
AAV, and has been continued for prolonged periods to 
maintain remission. However, the dangers of high cumu-
lative toxicity, particularly bladder cancer and myelo-
proliferative disease, have led to arguments for safer 
therapies [9]. Th e CYCAZAREM trial compared con-
tinued cyclophospha mide 1.5 mg/kg/day after remission 
induction to a switch to azathioprine 2  mg/kg/day [28]. 
No diff erence in subse quent relapse rate or other end-
points was seen at 18  months, and this study has 
validated a sequential approach to treatment with cyclo-
phosphamide with drawal at the time of remission.
Methotrexate
Th e WEGENT study randomised 126 patients to receive 
either methotrexate or azathioprine as maintenance 
therapy after successful induction of remission with 
cyclo phosphamide [55]. Th ere were no diff erences 
between groups in either relapse or toxicity. Use of 
methotrexate is usually restricted to those with creatinine 
<150 μmol/l (1.8 mg/dl).
Glucocorticoids
Th ere is variance in current practice regarding the use of 
prednisolone for remission maintenance. A review of 
published randomised trials in which the glucocorticoid 
protocol was defi ned found by multivariate analysis that 
glucocorticoid withdrawal was the strongest predictor for 
relapse [52].
Alternative remission maintenance therapies
A study involving 64 patients with GPA, comparing 
metho trexate (20  mg weekly) with lefl unomide (30  mg 
daily) as a maintenance therapy, was terminated early due 
to a higher major relapse rate in the methotrexate group 
(46%) compared with the lefl unomide group (23%) [56]. 
However, this was balanced by an increased rate of severe 
adverse events in the lefl unomide group. Th e position of 
lefl unomide as a remission maintenance agent remains 
uncertain.
Long-term treatment with sulfamethoxazole/trimetho-
prim is based on the assumption that controlling bacterial 
infection will reduce relapse risk [18]. When dosed at 
sulfamethoxazole/trimethoprim 960 mg twice a day in 
GPA there were reduced respiratory tract infec tions and 
respiratory tract relapses in a double-blind trial [57]. It is 
unclear whether this antibiotic has intrinsic antivasculitis 
activity separate from its antibiotic role, but the study 
supports the need for careful microbiological evaluation 
and treatment in GPA, especially in patients with 
respiratory tract involvement pursuing a relapsing course.
Mycophenolate mofetil
Following its success in the fi eld of transplantation, MMF 
has been considered as an alternative to azathioprine for 
remission maintenance therapy in AAV. Results from a 
small pilot study in 11 patients were promising, with only 
one relapse occurring after 14 months of follow-up [58]. 
Th e IMPROVE randomised study that compared MMF 
2  g/day and azathioprine 2  mg/kg/day as maintenance 
agents after cyclophosphamide induction in 174 patients, 
however, found an increased hazard ratio of 1.7 for 
relapse in the MMF group, and a shorter time to relapse 
[59]. MMF cannot be recommended as a fi rst-line 
remission maintenance agent in AAV but it may have a 
role for patients intolerant of azathioprine for whom 
methotrexate is contraindicated by renal failure.
Refractory disease
Patients with refractory disease encompass those who 
have disease progression or inadequate disease control 
despite induction therapy; those who relapse on main te-
nance immunosuppression, and those who are intolerant 
of standard therapy, most commonly cyclophosphamide. 
Refractory disease has been defi ned in a European 
League Against Rheumatism statement to facilitate 
further clinical investigation [25]. In such challenging 
patients, it is important to identify underlying drives such 
as infection or malignancy, and then to consider whether 
further immunosuppressive agents or alternative agents 
are indicated.
Rituximab is now the preferred agent for refractory 
disease [41]. Rituximab was more eff ective than cyclo-
phosphamide in the relapsing subgroup of the RAVE trial 
[40], although a retrospective series suggests it is less 
eff ective for granulomatous lesions, especially orbital 
masses than for vasculitic manifestations [60].
Additional agents
Intravenous immunoglobulin
Small studies have demonstrated a benefi t of IVIg in 
persistent disease [61,62]. Postulated mechanisms for 
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action of IVIg include the interference of binding of 
ANCA to their antigens through idiotypic mechanisms 
and the inhibition of ANCA-induced neutrophil activa-
tion [63,64]. Th irty-four patients with persistent disease 
activity were randomised to receive either IVIg (a single 
course at 2  g/kg) or placebo in a double-blind trial. 
Fourteen of 17 patients in the IVIg group as compared 
with 6/17 patients who received placebo had a reduction 
in disease activity, but this eff ect was not sustained 
beyond 3  months [65]. IVIg has also been used to 
maintain remission in patients with refractory disease 
[66]. Cost and limited availability have been barriers to 
the use of IVIg; however, it remains an alternative to 
consider in sepsis or pregnancy in order to minimise or 
avoid the use of standard agents.
TNF blockade
TNF blockade ameliorates disease in experimental 
models of AAV [67]. However, a benefi cial eff ect of TNF 
blockade in human disease has been more diffi  cult to 
demonstrate. Etanercept did not improve the rates of 
stable remission in GPA when added to glucocorticoids 
and cyclophosphamide or methotrexate [68]. Rates of 
serious adverse events exceeded 50% in both groups and 
a possible increase in solid malignancies was recorded in 
the etanercept group [69]. All cases of malignancy 
occurred in patients with prior cyclophosphamide 
exposure, however, and TNF blockade should therefore 
be avoided in these patients [70]. Both infl iximab and 
adalimumab have been proposed as adjunctive agents in 
renal vasculitis and a potential for steroid sparing has 
been demonstrated [71-73]. Prolonged infl iximab for 
refractory AAV has been complicated by infection and 
relapse.
Alternative strategies
T-cell-targeted agents
T-cell depletion with anti-thymocyte globulin led to 
remissions in refractory AAV in the SOLUTION trial but 
was poorly tolerated [74]. Alemtuzumab, an anti-CD52 
humanised monoclonal antibody, causes similar pro-
found lymphocyte depletion. A retrospective cohort 
study found remission of vasculitis in 60/71 (85%) 
refractory AAV patients after 134  mg alemtuzumab. A 
minority had sustained treatment-free remissions for 
many years, but 43/60 (72%) patients relapsed after a 
median of 9  months [24]. Retreatment was eff ective. 
Infective morbidity was high in those over 50  years old 
and with fulminant disease or vital organ failure. Th ese 
results have confi rmed a pathogenic role for T cells and 
the potential for T-cell depletion to produce sustained 
remissions. A trial of abatacept that blocks co-stimulation 
via CD28 in GPA is ongoing (ClinicalTrials.gov: 
NCT00468208).
Gusperimus
Gusperimus (previously termed 15-deoxyspergualin) is a 
synthetic analogue of the antibiotic spergualin, and 
suppresses lymphocyte and macrophage function and 
impairs neutrophil production. Forty-two of 44 (95%) 
patients with relapsing GPA responded to six cycles, each 
lasting 21 days with a 7-day washout period, of 0.5 mg/kg 
gusperimus, followed by azathioprine for 6 months [75]. 
Twenty of 44 (45%) patients achieved complete remission, 
although 43% of patients relapsed a median of 6 months 
after achieving remission. Severe adverse events occurred 
in 53% of patients and were predominantly leucopaenias, 
although they rarely led to treatment discontinuation. 
Extended courses of gusperimus as a maintenance agent 
have been shown to be eff ective and relatively safe 
[76,77].
Autologous stem cell transplantation
Th ere is limited experience of stem cell transplantation in 
vasculitis. In the 15 cases recorded in the European 
Blood and Marrow Transplantation database there was a 
response rate of over 90%, although relapses still 
occurred [78]. Th is approach is yet to be evaluated pros-
pectively, and appropriate patient selection – avoiding 
those with high prior cyclophosphamide exposure and 
irreversible end organ damage – is crucial in view of the 
high risk of complications.
Churg-Strauss syndrome
Although a form of AAV, the treatment of CSS has a 
number of distinct features. Glucocorticoid therapy alone 
may be suffi  cient, and patients are stratifi ed on the basis 
of the Five Factor Score. Cardiac, gastrointestinal and 
central nervous system involvement are adverse prog-
nostic features, as is creatinine >140  μmol/l and 
proteinuria >1  g in 24  hours [79]. A total 93% of 72 
patients with a Five Factor Score of 0 achieved remission 
with glucocorticoids alone, although 35% relapsed on 
prednisolone taper, and many required long-term 
maintenance glucocorticoids in order to control asthma 
[80].
Cyclophosphamide is the fi rst-line therapy for those 
with any adverse prognostic features. Th is treatment is 
highly eff ective when administered at a dose of 
600  mg/m2 every 2  weeks for a month and 4-weekly 
thereafter, with 87.5% of 48 patients achieving remission. 
Cumulative cyclophosphamide exposure infl uences 
relapse risk, however, with 85.7% of patients relapsing 
after six doses compared with 61.9% after 12 doses [81].
Regardless of disease severity, relapses are common, 
and current maintenance strategies for CSS are as for 
GPA and MPA. Rituximab has been shown to be 
effi  cacious in refractory CSS. Th is observation is based 
on only 20 reported cases, however, and there were two 
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reports of severe bronchospasm during rituximab 
infusion, which have raised concerns over possible 
hypersensitivity reactions triggered by rituximab in CSS 
[82]. In both situations, antihistamines but not steroids 
were administered at the time of rituximab infusion, and 
it may be that co-administration of intravenous steroids 
may reduce this risk.
IL-5 is an important survival factor for eosinophils, and 
mepolizumab (a monoclonal antibody directed against 
IL-5) is a promising novel therapeutic agent. Two pilot 
studies, using monthly mepolizumab infusions but 
involving only 17 patients in total, have demonstrated the 
effi  cacy and steroid sparing potential of mepolizumab in 
CSS [83,84]. Relapses were common on discontinuation 
of the drug, however, and larger, longer-term studies of 
this approach are required.
Future therapies
With the demonstration of the effi  cacy of rituximab in 
AAV, other B-cell-targeted therapies hold potential. Th e 
humanised anti-CD20 and anti-CD22 antibodies ocreli-
zu mab, ofatumumab and epratuzumab have diff erences 
in pharmacodynamics and frequency of antiglobulin 
responses compared with rituximab [85]. Th e B-
lymphocyte-stimulating protein (BLyS; also known as 
BAFF), a B-cell survival factor, is a further target. BLyS 
exerts its modulatory eff ect on B cells via three receptors; 
the transmembrane activator and calcium-modulator 
and cyclophilin inhibitor; B-cell maturation protein; and 
the BAFF receptor. Patients with active untreated GPA 
have signifi cantly higher serum BLyS levels than healthy 
controls [86]. Also, following B-cell depletion with 
rituximab in SLE, BLyS levels signifi cantly increase and 
then normalise as B-cell populations recover [87]. B-cell 
maturation protein is found on the surface of plasma cells 
and BLyS seems to protect lymphoid resident B cells 
from depletion, so BLyS inhibition may reduce plasma 
cell numbers [88] and enhance the susceptibility of 
tissue-residing B cells to depletion [89]. Belimumab is a 
humanised monoclonal antibody that inhibits BLyS. 
Effi  cacy and tolerability when added to standard therapy, 
but without a steroid-sparing eff ect, have recently been 
demonstrated in two phase III clinical trials in patients 
with SLE, without signifi cant renal involvement. 
Belimumab may yet prove to be very useful in AAV.
Co-stimulatory blockade, which aims to prevent 
autoreactive T-cell activation by B cells or other antigen-
presenting cells, should work in AAV. Abatacept (a 
CTLA4-Ig fusion protein) is under evaluation in GPA. 
Further biological agents targeting downstream cytokines 
are in trials in other autoimmune diseases, such as 
tocilizimab (an anti-IL-6 agent) in rheumatoid arthritis 
and IL-17 blocking agents in Crohn’s disease. Historically, 
many treatments for AAV have been adopted from other 
autoimmune diseases, and at least some of these newer 
biological agents used presently for other indications will 
probably be tried in AAV.
Other therapeutic mechanisms of relevance to 
vasculitis include inhibitors of downstream infl ammatory 
signalling pathways. After phosphorylation, spleen tyro-
sine kinase initiates several signalling cascades involving 
phosphatidylinositol-3-kinase that lead to aberrant 
neutrophil responses – including release of superoxide, 
which in turn leads to tissue damage. Inhibition of spleen 
tyrosine kinase in both mouse models and in human 
rheumatoid arthritis has exerted a positive clinical eff ect 
[90,91]. Inhibition of phosphatidylinositol-3-kinase 
suppresses infl ammation in mouse models of rheumatoid 
arthritis and SLE [92]. Although the pathology of AAV 
contains few immune deposits, complement depletion 
has abrogated experimental myeloperoxidase-ANCA 
renal vasculitis and is a potential target in human disease.
Discussion
Th e introduction of combined glucocorticoid and 
immuno suppressive therapy transformed the survival of 
patients with systemic vasculitis. Although there has 
been little change in the actual agents used to treat AAV, 
there has been considerable progress in optimising 
treatment regimens to minimise toxicity [93]. Despite 
these eff orts, however, cyclophosphamide and high-dose 
glucocorticoids remain toxic and 10% of patients are 
intolerant of these therapies. In addition, relapsing disease 
is common, with over 50% of patients experi encing a 
relapse within 5 years despite continued immuno suppres-
sion. Furthermore, refractory disease aff ects 10 to 20% of 
patients and poses a signifi cant management challenge. 
Th ere is therefore a clear need for more effi  cacious and 
safer therapies.
Rituximab is the best studied biological agent in AAV. 
Th e recently published randomised controlled trials 
RITUXVAS and RAVE have shown that rituximab is 
similar to cyclophosphamide, in terms of both effi  cacy 
and safety, for induction of remission in AAV in the short 
term. Subgroup analysis in the RAVE trial found the 
effi  cacy of rituximab to be superior to at 6 months for 
patients with relapsing disease.
Potential adverse eff ects of any new therapy must be 
carefully evaluated prior to recommendation of use. 
Infection, particularly in the context of hypogamma-
globulinaemia, is a concern following administration of 
rituximab. In a retrospective cohort of 105 patients with 
primary systemic vasculitis or SLE, 39% developed a mild 
infection, most commonly of the urinary tract, chest or 
upper respiratory tract. A total 28.5% of patients 
developed a severe infection, which is higher than in 
studies of rituximab in rheumatoid arthritis but lower 
than in vasculitis trials using alemtuzumab or 
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deoxy spergualin. Patients with low IgG and IgM levels 
have been shown to be at signifi cantly increased risk of 
infection, and immunoglobulin levels, as well as white 
cell counts, should be routinely monitored following 
rituximab administration [94]. In a retrospective series, 
late-onset neutropaenia occurred in 3/13 patients with 
GPA, all of whom developed infection needing intra-
venous antibiotics [95]. Further study is required into 
longer-term outcomes after rituximab treatment, includ-
ing cardiovascular disease, infertility and malignancy.
Concern has been expressed regarding the develop-
ment of progressive multifocal leucoencephalopathy, an 
opportunistic infection caused by the JC virus. At least 57 
cases have been reported following rituximab therapy, 
four in patients with autoimmune disease (two SLE 
patients, one rheumatoid arthritis patient and one immune 
thrombocytopaenia patient) [96]. Th is association is 
confounded by the use of immunosuppression prior to 
the administration of rituximab, and the observation that 
progressive multi focal leucoencephalopathy is seen in 
patients with autoimmune disease not treated with 
rituximab. Unfortunately, these reports highlight the 
possibility of rare, severe, adverse eff ects that may not be 
detected in clinical trials. It is important that patients 
who receive new biological agents enter registry follow-
up, to document late outcomes and side eff ects. Relapses 
are common after rituximab, and maintenance strategies 
are required that keep patients well yet avoid compli-
cations of prolonged B-cell depletion.
Improved patient subgrouping and tailoring of therapy 
will reduce unnecessary exposure to toxic therapies. 
Older people pose particular challenges. Th e peak 
incidence of AAV occurs in the age group of 65 to 
70  years. One-year mortality is 23% in those aged over 
60  years, compared with just 5% in the under-60 age 
group. Much of the excess mortality is due to infection. 
More attention is being focused on older people. Th e 
CORTAGE study, coordinated by the French Vasculitis 
Study Group, is comparing low-dose glucocorticoids 
with standard-dose glucocorticoids, with standard 
immuno suppression in patients over 65 years old. Newer 
biomarkers are required to predict treatment response, 
relapse risk and drug selection. Urinary monocyte 
chemoattractant protein-1 correlates with the degree of 
active vasculitis on renal biopsy and may become useful 
in renal vasculitis [97]. With advances in understanding 
of the genetic basis of disease and early results of 
transcriptome analysis, there is a real possibility that 
other clinically useful tests will become available.
Advances in classifi cation and evidence-based therapy 
of vasculitis have resulted from collaborative networks 
both within and between countries. To date, there has 
been little pharmaceutical investment in these disorders. 
With increasing physician collaboration and industry 
interest in rare diseases, progress is likely to accelerate. 
Consensus recommendation statements have been pub-
lished that will lead to harmonisation of therapy. With 
the establishment of registries and quality indicators 
there is hope that the variable quality of care that patients 
have received in the past will be improved.
Conclusion
Considerable progress has been made over recent years 
in refi ning the use of traditional immunosuppressive 
agents, namely glucocorticoids and cyclophosphamide, 
in systemic vasculitis, with the objective of minimising 
exposure and hence toxicity. Progress in classifying 
disease severity has provided the rationale to tailor the 
potency of immunosuppressive regimes to the extent of 
disease. Th is has facilitated the stratifi cation of patients 
into a number of randomised controlled trials looking at 
newer immunosuppressive agents (Table 2).
However, the pace of change is accelerating with 
greater understanding of the pathogenesis of vasculitis, 
and a number of targeted biological agents are entering 
clinical use. Th ere is an ongoing need for improved 
therapies for patients who are intolerant of current 
immunosuppression, and for those who pursue a 
relapsing or refractory course. A range of therapeutic 
agents is likely to be required for a condition as hetero-
geneous as systemic vasculitis. Th e effi  cacy, safety and 
tolerability of each agent must be thoroughly assessed, 
however, and the international collaborative clinical 
networks established in the vasculitis community will 
make it possible to develop this evidence base.
As the number of therapeutic options grows, the treat-
ment of vasculitis will probably become more complex 
for clinicians. With the introduction of biomarkers to 
more accurately assess disease activity and relapse risk, 
however, we should aim to simplify treatment for patients 
by individually tailoring their immunosuppressive regi-
men. As disease control improves, we should focus more 
on longer term causes of morbidity such as cardiovascular 
disease and on important patient-centred outcomes, 
including quality of life.
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